AIDS 2010
Half of Children Born to HIV Positive Mothers Do Not Receive Preventive Antiretroviral Drugs
- Details
- Category: Children & Adolescents
- Published on Friday, 06 August 2010 13:56
- Written by Liz Highleyman
Only about half of babies born to HIV positive mothers in 4 African countries received at least a minimum preventive dose of nevirapine (Viramune) immediately after birth to reduce the risk of mother-to-child transmission, according to a study in the July 21, 2010 Journal of the American Medical Association, a special HIV/AIDS issue coinciding with the XVIII International AIDS Conference (AIDS 2010) last month in Vienna. The World Health Organization (WHO) has released new guidelines recommending that all women with HIV should receive antiretroviral drugs to protect against HIV transmission during pregnancy, delivery, or breastfeeding, and that diagnostic testing should be expanded for infants to enable those infected to receive prompt treatment.
AIDS 2010: Investigational HIV Drug TBR-652 Reduces Viral Replication and May Dampen Inflammation
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 03 August 2010 13:56
- Written by Liz Highleyman
Tobira Pharmaceuticals' TBR-652, an experimental drug that blocks both the CCR5 and CCR2 cell surface receptors, has the dual effect of inhibiting HIV and affecting a biomarker associated with inflammation, according to data presented at the XVIII International AIDS Conference (AIDS 2010) last month in Vienna. TBR-652 was generally well-tolerated and a Phase 2b clinical trial is planned for early next year.
AIDS 2010: Majority of HIV Positive People on Antiretroviral Therapy May Have Reduced Bone Density
- Details
- Category: Bone Loss
- Published on Tuesday, 03 August 2010 13:56
- Written by Liz Highleyman
About half of people with HIV taking antiretroviral therapy (ART) in a Spanish study had low bone mineral density, and another quarter had more severe bone loss, researchers reported at the XVIII International AIDS Conference (AIDS 2010) last month in Vienna. This study found that bone loss was associated with use of tenofovir and protease inhibitors, a finding also supported by results of the ACTG 5142 trial in the U.S.
AIDS 2010: Switching from Boosted Protease Inhibitor to Raltegravir Maintains Viral Suppression in Absence of NRTI Resistance
- Details
- Category: HIV Treatment
- Published on Tuesday, 03 August 2010 13:56
- Written by Liz Highleyman
Switching from a ritonavir-boosted protease inhibitor to the integrase inhibitor raltegravir (Isentress) can maintain viral load at an undetectable level for most patients, but those with pre-existing nucleoside/nucleoside reverse transcriptase inhibitors (NRTIs) resistance mutations have an increased risk of virological failure if the drug is taken only once-daily, according to 2 studies from Spain presented at the XVIII International AIDS Conference (AIDS 2010) last month in Vienna.
HIV/HCV Coinfection, but Not HIV Alone, Raises Risk of Liver-related Death
- Details
- Category: HIV/AIDS Epidemiology & Mortality
- Published on Tuesday, 03 August 2010 01:20
- Written by Liz Highleyman
HIV positive people coinfected with hepatitis C virus (HCV) had an elevated mortality rate compared with the general population in Spain, but this was not the case for individuals with HIV alone, according to a study presented at the XVIII International AIDS Conference (AIDS 2010) last month in Vienna.
More Articles...
- AIDS 2010: Early Antiretroviral Therapy during Tuberculosis Treatment Improves Survival
- AIDS 2010: Studies Explore NRTI-sparing Antiretroviral Regimens Using New Drug Classes
- AIDS 2010: Oral Tenofovir for Pre-exposure Prophylaxis Appears Safe and Does Not Discourage Safer Sex
- AIDS 2010: Does Nevirapine Improve Response to Interferon-based Therapy in HIV/HCV Coinfected Patients?
Web Design and Development by